Mission Bio, based in South San Francisco, offers the Tapestri Platform for single-cell multi-omics and is known for generating DNA and protein data from the same cell. The company recently added targeted gene expression analysis and launched a Single-Cell Targeted Genotype and Gene Expression assay that profiles DNA and RNA from over 10,000 single cells in one assay. Mission Bio plans to broaden the platform to full tri-omics—simultaneous profiling of DNA, RNA, and protein—to support applications including patient stratification, safety assessments, and high-resolution MRD assays. The company reports strong traction with biopharma customers and industry partnerships, including a collaboration with Integrated DNA Technologies (IDT), and intends to expand commercial reach via distribution agreements. Mission Bio also expanded its commercial leadership by appointing Matthew H. Cato as Chief Commercial Officer. Recent equity financing will fund continued platform innovation, commercial growth, and accelerated clinical adoption across multiple cancer segments. Mission Bio develops the Tapestri single-cell multi-omics platform that measures DNA and protein changes within the same single cell to link genotype and phenotype. The platform is used to optimize clinical trials for targeted, precision cancer therapies and to validate genome-editing outcomes. Tapestri’s single-cell resolution helps rule out confounding effects that appear in bulk analyses, improving assessment of therapeutic impact. The company’s technology has been used by pharmaceutical and therapeutic companies (including Agios, LabCorp and Onconova Therapeutics) and at major cancer research centers such as UCSF, Stanford and Memorial Sloan Kettering. Mission Bio intends to scale the Tapestri platform to expand its use in clinical trials and genome-editing validation. The company has raised capital to date to support that scaling effort. Mission Bio is a South San Francisco–based single-cell DNA analysis and precision genomics company spun out of research at the University of California, San Francisco and led by CEO Charlie Silver. Its core product is the Tapestri® Platform, a targeted single-cell DNA sequencing platform that enables detection of heterogeneity in disease progression and treatment response. The Tapestri platform comprises an instrument, consumables, and analysis software that integrate with existing NGS workflows. Application areas include blood cancers, solid tumors, and genome editing validation. The company intends to use new funds to scale Tapestri by expanding the market for blood cancer research, broadening its scope to CRISPR applications, and extending into global markets. Mission Bio has raised more than $50M in total funding. Mission Bio is a South San Francisco developer of single-cell DNA analysis technology and the Tapestri precision genomics platform. Tapestri combines an instrument, consumables and software using proprietary droplet microfluidics to provide DNA accessibility at the single-cell level. The platform has throughput up to 10,000 cells, enabling detection of genomic variability within and across cell populations to support precision medicine research and clinical applications. Led by CEO Charlie Silver and based on Adam Abate's work at UCSF, Mission Bio intends to launch Tapestri and ship its first AML application in December 2017. With Series A funding, the company began a Custom Panel Grant Program to fund researchers building custom panels and will accept commercial panel orders in the first half of 2018. Mission Bio has secured NIH and NSF grants and won industry awards including the QB3@953 Amgen Golden Ticket and the CYTO Innovation Award in 2016. Mission Bio is developing a proprietary microfluidic, droplet‑based platform for high‑throughput single‑cell nucleic acid characterization. Its tools target research applications in oncology and immunology where cellular heterogeneity is critical. The company aims to commercialize a single‑cell genomics system for academic researchers as well as pharmaceutical and biotech customers to enable precision biology. Mission Bio spun out of UCSF three years ago and has received NIH and NSF grants. It has also won awards including the QB3@953 Amgen Golden Ticket and the CYTO Innovation Award. Earlier seed funding came from Tech Coast Angels, Keiretsu Forum and other seed‑stage investors; the company recently secured additional seed investment from Life Science Angels to support commercialization.

Total raised

$110M

Funding rounds

5

Latest round

Series C

Latest activity

Aug 2020